Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 4
Submit an article Journal homepage
8
Views
2
CrossRef citations to date
0
Altmetric
Research

Patent Analysis Central & Peripheral Nervous Systems: Anxiolytics: Patent analysis 1990–1995

Peter C Bates 31 Jacksons Lane, Great Chesterford, Saffron Walden, Essex, CB10 1SH
Pages 379-384 | Published online: 29 Feb 2008

References to Primary Literature

  • LANE R, BALDWIN D, PRESKORN S: The SSRls: advan-tages, disadvantages and differences. J. Psychopharma-col. (1995) 9(Suppl.):163–178.
  • SAXENA PR: Modern 5-HT receptor classification and5-HT based drugs. Exp. Opin. Invest, Drugs (1994) 3: 513–523.
  • SAXENA PR: Serotonin receptors: subtypes, functionalresponses and therapeutic relevance. Pharmacol. Ther. (1995) 66339–368.
  • NUTF D: The anxiety factor in depression. J. Psychophar-mac. (1995) 9(Suppl.):185–189.
  • PODONA T, GUARDIOLA-LEMAITRE B, CAIGNARDetal.: 3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HTIA receptor ligands and potential anxiolytic agents. J. Med. Chem. (1994) 37:1779–1793.
  • CUTLER NR, SRAMEK JJ, HESSELINK JMK et al.: A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective mut fleeter triaL J. Clin. Psychopbarmacol. (1993) 13:429–437.
  • THOMPSON DM, AUTA J, GUIDOITI A, COSTA E: Imi-dazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit In monkeys. J. Pharmacol. Exp. Ther. (1995) 273:1307–1312.
  • MUMFORD GK, RUSH CR, GRIFFITHS RR: Abecarnil andalprazolam in humans: behavioral, subjective and rein-forcing effects. J. Pharmacol, Exp. Ther. (1995) 272:570–580.
  • BALLENGER JC, MCDONALD S, NOYES R et al.: The firstdouble-blind, placebo-controlled trial of a partial ben-zodiazepine agonist abecarnil (Z1( 112119) in general-ised anxiety disorder. Psychopharmacol. Bull. (1991) 27:171–179.
  • BUSTO U, KAPLAN HL, ZAWERTAILO L, SELLERS EM: Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin. Pharmacol. Ther. (1994) 55:451–463.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.